Oral Contraceptive Pill Pretreatment in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Using the Gonadotrophin Releasing Hormone Antagonist Protocol (A Randomized Controlled Trial)

Abstract 700 women with PCOS undergoing IVF/ICSI using flexible GnRH antagonist protocol, were included in the study, and randomized to either OCP pretreatment (n = 350), or no pretreatment (n = 350). The latter group received OCP pretreatment in the form of 30µg ethinyl estradiol / 3mg drospirenone...

Full description

Saved in:
Bibliographic Details
Published inQJM : An International Journal of Medicine Vol. 116; no. Supplement_1
Main Authors Tamara, Tarek Fathy, El-Saed Abou Gamrah, Amgad, Gomaa, Mostafa Fouad, Abbas, Ahmed Mohamed, El-Sawy, Khaled Afifi
Format Journal Article
LanguageEnglish
Published 23.08.2023
Online AccessGet full text

Cover

More Information
Summary:Abstract 700 women with PCOS undergoing IVF/ICSI using flexible GnRH antagonist protocol, were included in the study, and randomized to either OCP pretreatment (n = 350), or no pretreatment (n = 350). The latter group received OCP pretreatment in the form of 30µg ethinyl estradiol / 3mg drospirenone (Yasmin®, Bayer AG, Berlin, Germany) pills for an interval of 21 to 28 days; after which COH was started following a 5-day pill wash-out period. OCP-pretreated PCOS women had more retrieved oocytes, albeit, on the expense of increased gonadotropin consumption. However, this increased oocyte yield did not translate to a significant effect on conception rates among intended-to-treat PCOS woman receiving OCP pretreatment. Conversely, it shifted among OCP-pretreated women who actually started COH cycle, to a significant 18% reduction in the probability of successful pregnancy.
ISSN:1460-2725
1460-2393
DOI:10.1093/qjmed/hcad069.551